Table 2.
Predictive value of miRNA-200 family expression for disease outcomes.
| Study | Samples | miRNA 200 Family Expression | Conclusions Made by Authors |
|---|---|---|---|
| Nam et al. [96]; Microarray with 377 (314 human) mirVana miRNA probes (Ambion) | Samples: 20 serous ovarian cancer tissues: 9 chemo-resistant, 11 chemo-sensitive tumors; Controls: 8 normal ovarian tissues | Increased expression of miR-200a, 200b, 200c and 141 in tumor samples vs. normal tissue | High expression of miR-200a, 200b, 200c and 141 were significantly correlated with decreased progression-free survival as well as overall survival |
| Hu et al. [97]; qRT-PCR miRNA assays (Applied Biosystems) | 55 patients: 48 epithelial ovarian carcinomas and 7 primary peritoneal carcinomas | Disease recurrence and poor overall survival were associated with low miR-200a, 200b and 429 expression | miR-200b-429 cluster expression has prognostic value in EOC |
| Eitan et al. [98]; Custom microarray slide (Nexetrion®) with 900 miRNA probes | 57 patients who had undergone surgery for tumor resection: 19 Stage I patients, 38 Stage III patients; All received platinum based chemotherapy | miR-200a expression was higher in Stage I ovarian cancer compared to Stage II | The data set shows significantly higher expression of miR-200a in early stage disease correlating with improved survival |
| Marchini et al. [89]; G4470B human miRNA microarray (Agilent Technologies) with probes for 723 human miRNAs | 144 patients with Stage I EOC out of which 29 patients relapsed | Tumors with lower miR-200c levels seen in patients who relapsed | miR-200 expression could be used as an indication of relapse in Stage I tumors |
| Leskela et al. [88]; qRT-PCR using the miRCURY™ LNA miRNA assay kits (Exiqon) | 72 patients were studied for overall survival analysis; A subgroup of 57 patients with both advanced tumor stage and serous carcinoma histotype were studied for treatment response | miR-200 expression correlated with β-Tubulin III levels | Low miR-200 expression was seen in patients without complete response to paclitaxel when compared to patients with complete response; Low miR-200 expression had a trend towards poor survival |